Preprint Article Version 1 Preserved in Portico This version is not peer-reviewed

Geospatial Cellular Distribution of Cancer-Associated Fibroblasts Significantly Impacts Clinical Outcomes in Metastatic Clear Cell Renal Cell Carcinoma

Version 1 : Received: 24 May 2021 / Approved: 26 May 2021 / Online: 26 May 2021 (10:53:24 CEST)

A peer-reviewed article of this Preprint also exists.

Chakiryan, N.H.; Kimmel, G.J.; Kim, Y.; Johnson, J.O.; Clark, N.; Hajiran, A.; Chang, A.; Aydin, A.M.; Zemp, L.; Katende, E.; Chahoud, J.; Ferrall-Fairbanks, M.C.; Spiess, P.E.; Francis, N.; Fournier, M.; Dhillon, J.; Park, J.Y.; Wang, L.; Mulé, J.J.; Altrock, P.M.; Manley, B.J. Geospatial Cellular Distribution of Cancer-Associated Fibroblasts Significantly Impacts Clinical Outcomes in Metastatic Clear Cell Renal Cell Carcinoma. Cancers 2021, 13, 3743. Chakiryan, N.H.; Kimmel, G.J.; Kim, Y.; Johnson, J.O.; Clark, N.; Hajiran, A.; Chang, A.; Aydin, A.M.; Zemp, L.; Katende, E.; Chahoud, J.; Ferrall-Fairbanks, M.C.; Spiess, P.E.; Francis, N.; Fournier, M.; Dhillon, J.; Park, J.Y.; Wang, L.; Mulé, J.J.; Altrock, P.M.; Manley, B.J. Geospatial Cellular Distribution of Cancer-Associated Fibroblasts Significantly Impacts Clinical Outcomes in Metastatic Clear Cell Renal Cell Carcinoma. Cancers 2021, 13, 3743.

Abstract

Cancer-associated fibroblasts (CAF) are highly prevalent cells in the tumor microenvironment in clear cell renal cell carcinoma (ccRCC). CAFs exhibit a pro-tumor effect in vitro and have been implicated in tumor cell proliferation, metastasis, and treatment resistance. Our objective is to analyze the geospatial distribution of CAFs with proliferating and apoptotic tumor cells in the ccRCC tumor microenvironment and determine associations with survival and systemic treatment. Pre-treatment primary tumor samples were collected from 96 patients with metastatic ccRCC. Three adjacent slices were obtained from 2 tumor-core regions of interest (ROI) per patient, and immunohistochemistry (IHC) staining was performed for αSMA, Ki-67, and caspase-3 to detect CAFs, proliferating cells, and apoptotic cells, respectively. H-scores and cellular density were generated for each marker. ROIs were aligned, and spatial point-patterns were generated, which were then used to perform spatial analyses using a normalized Ripley's K function at a radius of 25μm (nK(25)). The survival analyses used an optimal cut-point method, maximizing the log-rank statistic, to stratify the IHC-derived metrics into high and low groups, and multivariable Cox regression analyses were performed accounting for age and International Metastatic RCC Database Consortium (IMDC) risk category. Survival outcomes included overall survival (OS) from the date of diagnosis, OS from the date of immunotherapy initiation (OS-IT), and OS from the date of targeted therapy initiation (OS-TT). Therapy resistance was defined as progression-free survival (PFS) <6 months, and therapy response was defined as PFS >9 months. CAFs exhibited higher cellular clustering with Ki-67+ cells than with caspase-3+ cells (nK(25): Ki-67 1.19; caspase-3 1.05; P = .04). The median nearest neighbor (NN) distance from CAFs to Ki-67+ cells was shorter compared to caspase-3+ cells (15 μm vs 37μm, respectively; P < .001). Multivariable Cox regression analyses demonstrated that both high Ki-67+ density and H-score were associated with worse OS, OS-IT, and OS-TT. Regarding CAFs, only a high H-score was associated with worse OS, OS-IT, and OS-TT. For caspase-3+, high H-score and density were associated with worse OS and OS-TT. Patients whose tumors were resistant to targeted therapy (TT) had higher Ki-67 density and H-scores than those who had TT response. Overall, this ex vivo geospatial analysis of CAF distribution suggests that close proximity clustering of tumor cells and CAFs potentiates tumor cell proliferation, resulting in worse OS and resistance to TT in metastatic ccRCC.

Keywords

metastatic clear cell renal cell carcinoma; cancer associated fibroblasts; Ki-67; spatial analysis; immunohistochemistry

Subject

Medicine and Pharmacology, Immunology and Allergy

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our Diversity statement.

Leave a public comment
Send a private comment to the author(s)
* All users must log in before leaving a comment
Views 0
Downloads 0
Comments 0
Metrics 0


×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.